ArticlePloS one2025
The global, regional and national burden of pancreatitis due to alcohol use: Results from the Global Burden of Disease Study 2021 and projections to 2040.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global landscape and knowledge structure of research on pancreatitis and gut microbiota: a bibliometric analysis based on WoSCC and Scopus (2006 - 2025).Frontiers in cellular and infection microbiology · 2026Pooled it
- Persistence of Mortality-Dominant Pancreatitis Burden Despite Declining Rates, 1990-2023: An Analysis of the Global Burden of Disease 2023 Study.Medical sciences (Basel, Switzerland) · 2026Article
- We Can't Work It Out: The Threat of Pancreatitis to Global Productivity Among Working Age Adults.Digestive diseases and sciences · 2026Article
- Global burden of acute pancreatitis attributable to high alcohol intake from 1990 to 2021: findings and prevention potential based on GBD 2021.BMC gastroenterology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcohol use is a major risk factor for pancreatitis and global mortality. Despite its impact, comprehensive analyses of the burden across regions and sociodemographic strata remain scarce. This study examines global trends (1990-2021) and projects future burdens to 2040.
methodData on Deaths and Disability-Adjusted Life Years (DALYs) attributable to alcohol-induced pancreatitis were retrieved from the 2021 iteration of the Global Burden of Diseases (GBD) database. Trends were analyzed, Age-Period-Cohort models quantified age, period, and cohort effects on Age-Standardized Mortality Rate (ASMR) and Age-Standardized Disability-Adjusted Life Year (ASDR). Associations with SDI were evaluated, burden decomposition applied, and projections made to 2040.
resultsGlobally, both age-standardized death rate (ASDR) and mortality ratio (ASMR) exhibited overall declines (EAPC for ASDR: -0.32%; ASMR: -0.27%), but the reduction was significantly smaller in males (ASDR-EAPC: -0.18%) compared to females (-1.34%). Notablly,Eastern Europe had the highest burden (ASDR: 64.03), High-income Asia-Pacific saw the largest declines (EAPC for ASDR: -2.45%; EAPC for ASMR: -2.96%), while Southeast Asia experienced the fastest increase (EAPC for ASDR: 1.98%; EAPC for ASMR: 2.13%). ASDR peaked at ages 45-49, with high-middle SDI countries showing the highest values. Period and cohort effects varied by SDI, with downward trends in high SDI countries and upward trends in lower SDI groups. Population growth and aging drove increases in deaths and DALYs, while epidemiologic changes reduced them. By 2040, deaths and DALYs will stabilize, ASMR will decline until 2034 then rise, and ASDR will decrease until 2035 then increase, driven by population growth.
conclusionAlcohol-related pancreatitis burden demonstrates striking gender, age, and geographic heterogeneity. Targeted policies for high-risk groups (middle-aged/elderly males) and regions (Eastern Europe, Low-middle SDI countries), coupled with preparedness for aging-related burden escalation, are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.